Publication | Closed Access

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

CardiomyopathyHeart FailureOmecamtiv MecarbilCardiovascular DiseaseSystolic Heart FailureMedicineCardiovascular PharmacologyDiastolic FunctionPharmacotherapyCardiac CarePharmacologyCardiologyCardiac Myosin Activator